TP53 rs1042522 polymorphism and early-onset breast cancer
dc.authorwosid | Taskin, ırmak Icen/AAA-6149-2021 | |
dc.contributor.author | Icen-Taskin, Irmak | |
dc.contributor.author | Irtegun-Kandemir, Sevgi | |
dc.contributor.author | Munzuroglu, Omer | |
dc.date.accessioned | 2024-08-04T20:47:22Z | |
dc.date.available | 2024-08-04T20:47:22Z | |
dc.date.issued | 2020 | |
dc.department | İnönü Üniversitesi | en_US |
dc.description.abstract | Background: Breast cancer is the leading cause of cancer deaths among women. Early-onset breast cancer is well recognized as it clinically differs from old-age diagnosed breast neoplasms. TP53 rs1042522 polymorphism relates to the risk of breast neoplasms, but this relationship in Turkish early-onset breast cancer patients has not been investigated yet. We aimed to search the relationship between TP53 rs1042522 polymorphism and young Turkish breast cancer patients. Materials and Methods: Ninety-six female breast cancer patients who were <= 40 years of age and 96 healthy controls were enrolled in our study. Participants were genotyped by the hybridization probe system. Results: We identified that the genotype frequencies of rs1042522 were significantly different between controls and cases (P = 0.027). Participants carrying CG genotype had also reduced breast cancer risk (odds ratio = 0.4196, 95% confidence interval: 0.1941-0.9067, P = 0.027). Our results revealed that there is an association between GG and CG + CC genotype groups with progesterone receptor (PgR) status (P = 0.0219). Conclusion: Our findings indicate that the CG genotype is a protective factor against breast neoplasms. No other clinicopathologic parameters except for PgR status were found to be related to rs1042522 polymorphism in young Turkish breast cancer patients. | en_US |
dc.description.sponsorship | Firat University Scientific Research Projects Unit [MF.16.31] | en_US |
dc.description.sponsorship | This work has been supported by Firat University Scientific Research Projects Unit with project number MF.16.31. | en_US |
dc.identifier.doi | 10.4103/jrms.JRMS_506_19 | |
dc.identifier.issn | 1735-1995 | |
dc.identifier.issn | 1735-7136 | |
dc.identifier.pmid | 32419782 | en_US |
dc.identifier.scopus | 2-s2.0-85085173243 | en_US |
dc.identifier.scopusquality | Q3 | en_US |
dc.identifier.uri | https://doi.org/10.4103/jrms.JRMS_506_19 | |
dc.identifier.uri | https://hdl.handle.net/11616/99303 | |
dc.identifier.volume | 25 | en_US |
dc.identifier.wos | WOS:000613241400005 | en_US |
dc.identifier.wosquality | Q3 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wolters Kluwer Medknow Publications | en_US |
dc.relation.ispartof | Journal of Research in Medical Sciences | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Breast neoplasms | en_US |
dc.subject | early onset | en_US |
dc.subject | genotype | en_US |
dc.subject | rs1042522 | en_US |
dc.subject | TP53 | en_US |
dc.title | TP53 rs1042522 polymorphism and early-onset breast cancer | en_US |
dc.type | Article | en_US |